go-v.orgdoi

Additional induction chemotherapy to concurrent chemotherapy and intensity-modulated radiotherapy with or without nimotuzumab in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis

Fangzheng Wang, Quanquan Sun, Chuner Jiang, Tongxin Liu, Rihito Aizawa, Masoto Sakamoto, Yuezhen Wang, Zhenfu Fu, Ming Chen · Journal of Cancer · 2018

  • DOI 10.7150/jca.20461
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2018

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2018

Abstract

Background: The aim of this study is to assess the survival benefits of additional induction chemotherapy before concurrent chemotherapy, intensity-modulated radiotherapy and nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma.Methods: Clinical data from 1104 nonmetastatic nasopharyngeal carcinoma patients diagnosed between May 2008 and April 2014 were retrospectively reviewed.All patients received addition of induction chemotherapy to concurrent chemoradiotherapy with or without nimotuzumab.A propensity score matched method was used to identify paired patients according to various covariates.Results: In total, 120 pairs were selected by propensity score matched method.At a median follow-up time of 56 months (10-99 months), the 5-year locoregional relapse-free survival, distant metastases-free survival, progression-free survival and overall survival rates in patients treated with nimotuzumab vs. without nimotuzumab were 91.6% vs.

91.1% (P= 0.957), 95.8% vs. 83.9%(P= 0.007), 87.4% vs. 81.3%(P= 0.225), 94.5% vs. 85.6% (P= 0.058), respectively.Multivariate analysis revealed that nimotuzumab was an independent prognosticator of OS and DMFS.Conclusions: Nimotuzumab is an effective treatment option for locoregionally advanced nasopharyngeal carcinoma, and the addition of induction chemotherapy to concurrent chemoradiotherapy and nimotuzumab could obtain the best survival benefits.

Open the resolved locator · 10.7150/jca.20461

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 04:38 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v09p0594.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.